Mineralys Therapeutics, INC. (MLYS) — 10-Q Filings

All 10-Q filings from Mineralys Therapeutics, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Mineralys Narrows Losses, Boosts Cash with $459M in Offerings — Nov 10, 2025 Risk: medium
Mineralys Therapeutics, Inc. (MLYS) reported a net loss of $36.9 million for the three months ended September 30, 2025, a significant improvement from the $56.3
Mineralys' Losses Mount Amid R&D Spend, Cash Position Strong — Aug 12, 2025 Risk: high
Mineralys Therapeutics, Inc. reported a net loss of $43.3 million for the three months ended June 30, 2025, an increase from $41.0 million in the prior-year per
Mineralys Therapeutics Files Q1 2025 10-Q — May 12, 2025 Risk: low
Mineralys Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, incorporated in Delaware, operates in the Pharmaceutical Preparat
Mineralys Therapeutics Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
Mineralys Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, incorporated in Delaware, operates in the Pharmaceutical Prep
Mineralys Therapeutics Files Q2 2024 10-Q — Aug 13, 2024 Risk: medium
Mineralys Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business
Mineralys Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
Mineralys Therapeutics, Inc. (MLYS) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Mineralys Therapeutics, Inc. filed a 10-Q report for the quarte

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX